Re-Registration Stability and Biocompatibility Triggers for Medical Devices in Egypt

1. Key takeaways

The stability and biocompatibility duties at the Egyptian re-registration stage follow the rules for locally manufactured devices. The baseline rule: a locally manufactured device that has undergone no change in packaging raw materials and for which a real-time stability study was submitted at first registration or during the validity period of the registration licence is not submitted again to the stability committee; where no study was submitted, it is assessed at re-registration. Three types of change trigger further work: a raw material change requires the biocompatibility study to be re-evaluated by the stability scientific committee; a sterilization method change requires a new stability study containing only sterilization validation together with a re-evaluation of the biological risk assessment; a packaging material or packaging size change requires a new stability study containing only packaging validation together with a re-evaluation of the biological risk assessment.

2. Legal basis

The rules draw on the registration guideline’s committee provisions and on the variation guideline’s stability clauses.

3. Expert insights

Insight 1: the re-registration stability duty is tied directly to whether a real-time study was filed at first registration.

Under the first heading of Section 10, devices with no change in packaging raw materials and a real-time stability study already submitted at first registration or during the licence validity period are not submitted to the committee again. The value of this rule lies in its timing: submitting a real-time stability study at first registration removes this step from re-registration ten years later. It is a compliance investment that can be made a decade in advance.

Insight 2: the consequences of the four change triggers differ, and companies often conflate them.

Section 10 distinguishes four triggers with distinct actions: (1) a raw material change means the biocompatibility study is re-evaluated by the stability scientific committee; (2) a sterilization method change requires a new stability study containing only sterilization validation plus a re-evaluation of the biological risk assessment; (3) a packaging material or packaging size change requires a new stability study containing only packaging validation plus a re-evaluation of the biological risk assessment; (4) a shelf life and/or storage condition change is assessed by the stability scientific committee. Items 2 and 3 call for a scope-limited new study plus a risk re-evaluation, not a full repeat of all studies, and this distinction directly affects re-registration cost.

Insight 3: re-evaluation of the biocompatibility study and re-evaluation of the biological risk assessment are two different actions.

The former (raw material changes) targets the study itself, which the committee must re-evaluate; the latter (sterilization and packaging changes) targets the risk analysis documentation, whose biological risk assessment must be re-evaluated. When preparing the re-registration package, companies should configure test reports or risk analysis documents according to the trigger type rather than bundling everything together.

Insight 4: Section 6.3 of the variation guideline and Section 10 of the registration guideline interlock in both directions.

GL.CAMD.003 Section 6.3 provides that specific changes to a registered device require the submission of a stability study dossier. This means the same change, if made during the licence validity period, goes through the variation procedure, while if it persists into re-registration, it is absorbed into the re-registration assessment. The endpoint of both paths is the same body of stability data, which argues for building the dataset once and reusing it.

Insight 5: the stability and biocompatibility committee has four submission scenarios, and re-registration is one of them.

Section 6 lists four scenarios: registration and re-registration of locally manufactured devices with no transactions in a reference country; packaging changes or additions, sterilization method changes or additions, and storage condition changes accepted by the variation department; shelf life extensions (re-registration or variation); and correction of a shelf life caused by an erroneous shelf life certificate submitted by the company. Re-registration appears in the first and third scenarios.

Insight 6: retained sample duties for local factories span the entire validity period.

Section 6, item First: when a local factory submits a stability study, the samples must be sealed by the Central Administration for Pharmaceutical Establishments Inspection, stamped by the entity conducting the study, have batch numbers consistent with the stability study, and be retained at the factory for the duration of the registration licence validity period. Measured against the 10-year validity period, the factory must be capable of ten years of retained sample management. That decision applies to stability studies conducted after January 2, 2018.

Insight 7: the April 16, 2026 announcement may reduce this set of duties substantially.

The EDA announced on April 16, 2026 that local factories holding CE certificates submitting registration or re-registration dossiers are exempt from submitting the reference-country FSC, stability studies and biocompatibility test reports, while the EDA retains the right to require them. As a practical estimate, the scope of application and implementing details follow the current announcement text on the EDA website. For factories combining local production with a CE certificate, the evidentiary burden of the three triggers can be significantly reduced, but complete exemption cannot be presumed.

4. Practical recommendations

The following steps align stability planning with the re-registration clock.

1. Submit the real-time stability study at first registration: it clears the committee step ten years later.
2. Build a change type to re-registration consequence mapping: four triggers map to three distinct actions.
3. Keep re-evaluation of the biocompatibility study separate from re-evaluation of the biological risk assessment, and configure documents accordingly.
4. Check for the four change types before re-registration and prepare the corresponding studies early.
5. Institute ten-year retained sample management at the local factory: sealing, stamping and matching batch numbers.
6. Share one body of stability data between variation and re-registration to avoid duplicate investment.
7. Assess the reduction effect of the 2026-04-16 CE announcement, while keeping a contingency plan for any requirement to supplement.

5. Verification checklist

• □ It has been confirmed whether a real-time stability study was submitted at first registration
• □ The presence of the four change types before re-registration has been checked (raw material / sterilization method / packaging material or size / shelf life and storage conditions)
• □ The document type for each change has been determined (study re-evaluation / scope-limited new study plus risk re-evaluation)
• □ The biocompatibility study was conducted by a recognized entity with ISO/IEC 17025 accreditation evidence
• □ Retained samples at the local factory (sealed, stamped, matching batch numbers, ten-year retention) are in place
• □ Stability data for variation and re-registration are archived in a unified system
• □ The exemption effect of the 2026-04-16 CE announcement has been assessed and a contingency plan prepared

Regulatory information verified as of October 29, 2026. The re-registration stability trigger rules in this article follow the current text of EDREX: GL.CAMD.002 Version 2, Sections 6 and 10, and EDREX: GL.CAMD.003 Version 3, Section 6.3.

• Egypt local support: GRZAN assists manufacturers from the Chinese mainland and overseas with EDA medical device registration, import approval and variation applications, including registration applicant pathway design (importing company, local factory, or Scientific Office), preparation for Scientific Committee evaluation, demonstration of free sale certificate routes from reference countries, Arabic labelling and instructions-for-use localization, and the setup of vigilance and periodic reporting systems.
• Service capabilities: product classification and risk grading (devices Class I–III, IVD Class A–D), registration and re-registration, applicability assessment for system registration and bundled registration, three-way variation classification, import approval and annual import plans, and support for vigilance reporting and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.